



PUSH DOCTOR

Push Doctor raises \$26.1M to help people live longer

Investment led by Accelerated Digital Ventures reflects massive potential of digital services across the globe

London, July 5th, 2017: Europe's largest digital health provider, [Push Doctor](#), today announced that it has raised \$26.1M in a Series B funding round led by Accelerated Digital Ventures ("ADV" – the venture investment company backed by Legal & General, Woodford Investment Management and the British Business Bank) and Draper Esprit, with participation from major European funds, Oxford Capital, Partech Ventures and Seventure Partners. This takes the total funding for Push Doctor to date to over \$37.5M.

Push Doctor is the first truly digital health consumer brand in the UK, connecting patients to a smart network of thousands of UK qualified GPs, giving them access to a doctor in as little as six minutes on any device.

The brand's founder and CEO, Eren Ozagir, explained how the firm will provide everyone with the opportunity to live longer, happier lives: "We have treated more cases digitally than anyone in Europe and consistently grown over 35% month-on-month for 16 months. As a result, we have a dataset that provides a unique view of the medical issues facing a nation. This has meant that we have been able to scope and create a data-driven digital health platform that will treat the whole person. No one before Push Doctor has provided consumers with access to a single digital health platform that combines responsive medicine and chronic condition management as well as fitness and nutritional conditioning."

This round of investment will enable Push Doctor to bring new products to market, the first of which will hit later this year. This will further expand the company's value-proposition for patients as it couples its market-changing instant access to doctors with complementary products and services.

Ozagir continued: "This recent funding round will see us boost our growth in customer numbers and take significant steps in our ambition to become the preferred consumer digital health care brand in the world."

Michael Dimelow, Head of Investment at ADV, remarked: "The health and wellbeing sector is perfectly positioned to benefit from digital technology innovation, and the UK is one of the best places from which to build a global business in this space. We're delighted to announce our investment in Push Doctor with its unique vision to build an open platform, where the entire industry can connect and collaborate. Equally, consumers will gain efficient and direct access to healthcare professionals. The Push Doctor team is tried and tested in building international internet propositions at scale, and we look forward to supporting them in their journey to build an industry-defining global healthcare platform."

Dr. Vishal Gulati, digital health investor at Draper Esprit, commented: "People's expectations around how, when and where they access healthcare have evolved. Push Doctor is the leading health provider which is addressing growing, unmet patient needs. By putting the patient experience first, the company is changing our relationship with healthcare, lowering the hurdle of access for both immediate needs and chronic, long term conditions. Having known the team for two years now, I am excited to continue working with them to build a product which reshapes patient experiences in the future."

Tom Bradley, Partner at Oxford Capital, said: “We continue to believe that digital health will change the way everyone interacts and manages their healthcare today, and in the future, which is why we invested in Push Doctor early and continue to today. This next phase of the brand’s development will see the whole team create a product set that truly reflects the needs of not just a nation, but a population generally, as we strive to make people healthier for the long term. This reflects our investment strategy of identifying potential market leaders early and supporting them through that transition from potential to leader.”

Isabelle de Cremoux, CEO & Managing Partner at Seventure Partner, stated: “Push Doctor’s digital health and wellness platform is well differentiated and has the potential to make a significant impact on the delivery of doctors’ services in the UK and beyond. We look forward to working with Eren and his team to expand the business and see Push Doctor fulfil its full potential.”

-ENDS-

Notes to editors

For more information, please contact:

pushdoctor@hotwirepr.com

+44 (0) 208 7608 2500

About Push Doctor

Push Doctor is Europe’s largest digital health brand – and began connecting patients to a smart network of thousands of UK qualified NHS GPs in as little as 6 minutes on any device. Providing nine out of ten patients with a resolution during their digital consultation.

Today the brand is evolving to encompass the widest range of medical, health, wellness and lifestyle products / services with the core goal of enabling its customers to live happier, longer lives.

Push Doctor. For Health. For Life

Speak to a GP online at PushDoctor.co.uk or via the iOS and Android apps anywhere in the World, seven days a week, 365 days a year, and receive diagnosis, referral letters, fit for work notes and if necessary, prescription medication.

For more information and to see a doctor online, visit www.PushDoctor.co.uk | @PushDr

“Push Doctor” and the “Shield” are the registered trademarks of Push Dr Limited.

About Accelerated Digital Ventures

ADV is a venture platform, created by operators and collaborators. Our team are entrepreneurs and business founders who have learnt the hard lessons, and want to pay them forward. ADV provides a full-scale model for venture, across the business lifecycle. We offer access to capital, coaching, customers and corporates. We champion the innovators - the people who build the large ‘difficult’ businesses that the UK is uniquely positioned to foster. The complex, technical, global ones. The businesses that are solving real world problems. Say hello at www.accelerated.ventures | @AcceleratedDV

About Draper Esprit

Draper Esprit is one of the most active venture capital firms in Europe, developing and investing in disruptive businesses building the future. We believe the best entrepreneurs in Europe are capable of creating global companies. We fuel their growth with long- term capital, access to international networks, and decades of experience building businesses. We are innovating the venture model and in June 2016 listed on the London Stock Exchange. We know it can take years to build the best businesses and this empowers us to invest for the

long haul. Draper Esprit is the European arm of the Silicon Valley- based Draper Venture Network with offices around the world and portfolio companies including Baidu, Skype, Space X and Tesla.

About Oxford Capital

Oxford Capital has been investing in early-stage companies since 1999. We aim to back entrepreneurs who are creating innovative solutions to big commercial, scientific or technological problems. Our London-based investment team has more than 70 years of combined experience, gained at leading venture capital firms in the UK and US. We invest in businesses all over the UK, and our current portfolio spans sectors including digital health, fin-tech, ecommerce, artificial intelligence & machine learning, and mobile gaming.

About Seventure Partners

With over €660m in assets under management as of the end of 2016, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in two fields: Digital technologies in France and Germany, and Life sciences across Europe, Israel and North America.

In Life sciences, the four areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology, and last but not least: the Microbiome, nutrition, foodtech and personalized medicine. Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage. Recently, Seventure Partners successfully launched Health for Life Capital™ which has attracted strategic investments from prestigious organizations including Danone, Tereos, Tornier, Lesaffre, Bel and Novartis, as well as entrepreneurs and financial institutions.

Seventure is a subsidiary of Natixis Global Asset Management. Natixis is the international corporate, investment, insurance and financial services arm of Groupe BPCE, the second-largest banking group in France.

For more details: www.seventure.com / Twitter @SeventureP

About Health For Life Capital™

Seventure Partners launched Health for Life Capital™, the first venture capital fund focused mainly on investments in the microbiome and nutrition space. Europe is the primary focus of the fund, but it also invests in North America, Israel and Asia. The €160m fund attracted strategic investments from prestigious organisations including Danone, Novartis, Tereos, Tornier, Lesaffre and Bel, as well as financial institutions and entrepreneurs. Health for Life Capital™ is managed by Seventure's Life sciences team.

About The Microbiome

The Microbiome, which consists in all the micro-organisms that reside in and on the human body, is an exciting and fast-developing new field at the interface of pharmaceuticals and nutrition, offering abundant opportunities for developing new medicines. The composition and functionality of the bacterial ecosystem forming a large part of the microbiome, in the gut and elsewhere, has been linked to various health conditions, among which acne, psoriasis and allergies, gastrointestinal ailments, Crohn's Disease, obesity, diabetes, autism, depression or cancer. There are approximately ten times more bacteria than human cells in the body, and over a hundred times more bacterial genes than human ones. The multitude of biological processes and indications affected by the bacterial ecosystem within the human microbiome, makes its balance critical to health. Understanding and maintaining an adequate balance of species within this complex ecosystem is an important goal for future medical progress, especially in the area of preventing and treating chronic diseases.

